A CONDITIONING PLATFORM WITH FLUDARABINE, BUSULFAN AND ATG CONDUCTS TO IDENTICAL PROMISING RESULTS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM BOTH MATCHED AND MISMATCHED UNRELATED DONOR

被引：0
|
作者：
Devillier, R. [1 ,2 ,3 ]
Furst, S. [1 ]
Crocchiolo, R. [1 ]
El-Cheikh, J. [1 ]
Castagna, L. [4 ]
Harbi, S. [1 ,2 ]
Granata, A. [1 ]
Chabannon, C. [1 ,2 ,3 ]
Calmels, B. [5 ]
Lemarie, C. [5 ]
Bouabdallah, R. [1 ]
Vey, N. [1 ,2 ,3 ]
Blaise, D. [1 ,2 ,3 ]
机构：
[1] Inst Paoli Calmettes, Hematol, Marseille, France
[2] Aix Marseille Univ, Marseille, France
[3] Ctr Rech Cancerol Marseille, Marseille, France
[4] Inst Clin Humanitas, Hematol, Milan, Italy
[5] Inst Paoli Calmettes, Cell Therapy, Marseille, France
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P367
引用
收藏
页码：156 / +
页数：2
相关论文
共 50 条
  • [1] A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
    Devillier, Raynier
    Fuerst, Sabine
    Crocchiolo, Roberto
    El-Cheikh, Jean
    Castagna, Luca
    Harbi, Samia
    Granata, Angela
    D'Incan, Evelyne
    Coso, Diane
    Chabannon, Christian
    Picard, Christophe
    Etienne, Anne
    Calmels, Boris
    Schiano, Jean-Marc
    Lemarie, Claude
    Stoppa, Anne-Marie
    Bouabdallah, Reda
    Vey, Norbert
    Blaise, Didier
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 83 - 87
  • [2] Fludarabine, busulfan, and thiotepa may be a promising conditioning regimen for myelofibrosis patients undergoing allogeneic stem cell transplantation
    Shouval, Roni
    Vega, Yakov
    Fein, Joshua A.
    Danylesko, Ivetta
    Tov, Noga Shem
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BONE MARROW TRANSPLANTATION, 2019, 54 : 204 - 205
  • [3] Fludarabine and ATG based conditioning regimen was effective in HLA-matched family and unrelated donor transplantation in patients with chronic myelogenous leukemia
    Dybko, J
    Wysoczañska, B
    Aba, A
    Lange, A
    BONE MARROW TRANSPLANTATION, 2001, 27 : S149 - S149
  • [4] Low dose busulfan and ATG with fludarabine as conditioning regimen was effective in sibling and unrelated donor HSCT in CML patients.
    Lange, Andrzej
    Sedzimirska, Mariola
    Dlubek, Dorota
    Jaskula, Emilia
    Mlynarczewska, Anna
    Sok, Agnieszka
    BLOOD, 2006, 108 (11) : 287B - 287B
  • [5] Fludarabin/Busulfan/Thiotepa/ATG is as an effective myeloablative conditioning protocol in adults undergoing unrelated donor stem cell transplantation
    Watson, Edmund
    Balassa, Katalin
    Fatobene, Giancarlo
    Lubowiecki, Marcin
    Cash, Rebecca
    Barton, Daja
    Ellis, Mandy
    Rowley, Lara
    Wareham, Denise
    Costa, Claudia
    Miller, Rachel
    Danby, Robert
    Rocha, Vanderson
    Peniket, Andy
    BONE MARROW TRANSPLANTATION, 2018, 53 : 273 - 274
  • [6] Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience
    Memoli, Mara
    Paviglianiti, Annalisa
    Malard, Florent
    Battipaglia, Giorgia
    Brissot, Eolia
    Mediavilla, Clemence
    Bianchessi, Antonio
    Banet, Anne
    Van de Wyngaert, Zoe
    Ledraa, Tounes
    Belhocine, Ramdane
    Sestili, Simona
    Lapusan, Simona
    Hirsch, Pierre
    Favale, Fabrizia
    Boussaroque, Agathe
    Bonnin, Agnes
    Vekhoff, Anne
    Legrand, Ollivier
    Mohty, Mohamad
    Dulery, Remy
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 419 - 427
  • [7] Comparable Allogeneic Hematopoietic Cell Transplantation Outcome Of Haplo-Identical Family Donor With Matched Unrelated/Mismatched Family Donor In Adult Aplastic Anemia
    Kim, Hawk
    Lee, Je-Hwan
    Joo, Young-Don
    Bae, Sung-Hwa
    Lee, Jung-Hee
    Kim, Dae-Young
    Jo, Jae-Cheol
    Park, Jae Hoo
    Lee, Won Sik
    Ryoo, Hun-Mo
    Park, Sang-Kyu
    Lee, Kyoo Hyung
    BLOOD, 2013, 122 (21)
  • [8] Reduced-intensity conditioning with fludarabine, busulfan, and 4 Gy total body irradiation followed by allogeneic unrelated donor bone marrow transplantation
    Hara, M.
    Nakase, K.
    Itakusu, K.
    Takeuchi, K.
    Nawa, Y.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S419 - S419
  • [9] HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED TOXICITY CONDITIONING (RTC)
    Hamadani, M.
    Craig, M.
    Abraham, J.
    Tse, W.
    Cumpston, A.
    Gibson, L. F.
    Remick, S. C.
    Leadmon, S.
    Elder, P.
    Hofmeister, C.
    Penza, S.
    Andritsos, L.
    Blum, W.
    Benson, D. M., Jr.
    Devine, S. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S306 - S306
  • [10] Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia
    Saraceni, Francesco
    Beohou, Eric
    Labopin, Myriam
    Arcese, William
    Bonifazi, Francesca
    Stepensky, Polina
    Aljurf, Mahmoud
    Bruno, Benedetto
    Pioltelli, Pietro
    Passweg, Jakob
    Socie, Gerard
    Santarone, Stella
    Yakoub-Agha, Ibrahim
    Lanza, Francesco
    Savani, Bipin N.
    Mohty, Mohamad
    Nagler, Arnon
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (10) : 1211 - 1219
12345